This inventor holds 30 USPTO granted patents and 4 published patent applications and 4 EPO patents, primarily in Semiconductor Manufacturing. Top assignees: Kabushiki Kaisha Toshiba, Mitsubishi Cable Industries, Ltd., Kabushiki Kaisha Topcon. Active years: 1997-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Nerima-ku, JP (2009)
- Yokohama, JP (2009)
- Saitama, JP (2013)
- Tokyo, JP (1997 - 2017)
- Hyogo, JP (2022)
- Shinagawa-ku, JP (2022 - 2024)
Company Filing History:
8 out of 53,286 
6 out of 219 
5 out of 1,033 
Years Active: 1997-2024
Areas of Expertise:
Title: **Shinji Yamaguchi: A Pioneering Innovator in the Field of Peptide Conjugates**
Introduction
Shinji Yamaguchi, based in Tokyo, Japan, is an esteemed inventor known for his significant contributions to biotechnology, particularly in the development of innovative peptides. With an impressive portfolio of 30 patents, Yamaguchi has demonstrated a commitment to advancing medical science through his inventions.
Latest Patents
Among his latest inventions are the KLK5 inhibitory peptide conjugates, which are designed to inhibit KLK5. These conjugates are Fc fusion peptides, incorporating the Fc region of human IgG1 or its fragments. The KLK5 inhibitory peptide conjugates feature amino acid sequences from a predefined list of SEQ ID NOs, including 34, 36, 38, 40, 42, 44, 46, 48, 96, 50, 52, 54, 56, 58, or 60. Additionally, Yamaguchi has developed pharmaceutical compositions containing these peptides that are engineered to treat KLK5-related diseases, showcasing the therapeutic potential of his innovations.
Career Highlights
Shinji Yamaguchi has had a stellar career, having worked with renowned companies such as Kabushiki Kaisha Toshiba and Mitsubishi Cable Industries, Ltd. His experience in these institutions has aided in the refinement of his inventive processes and has broadened his understanding of the industry.
Collaborations
Throughout his career, Yamaguchi has collaborated with distinguished individuals such as Kaoru Kumagai and Masamitsu Itoh. These partnerships have fostered an environment of creativity and innovation, leading to groundbreaking work in peptide technology.
Conclusion
Shinji Yamaguchi stands out as a leading figure in the field of peptide research and development. His innovative KLK5 inhibitory peptide conjugates represent a substantial advancement in the treatment of associated diseases. With a strong foundation in his career and valuable collaborations, Yamaguchi's future endeavors are anticipated with great interest within the scientific community.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile